$APVO

Aptevo Therapeutics Inc. (APVO): Submission of Matters to a Vote of Security Holders

Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On August 21, 2026, Aptevo Therapeutics Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. Stockholders considered four proposals outlined below, each o

Original reporting
Published Aug 21, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$APVO
Neutral
high confidence
Mentioned
$APVO
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$APVONeutralLow
01

Why it matters

The filing is a routine corporate governance disclosure with no immediate financial impact, serving primarily to satisfy regulatory reporting requirements.

02

Market read

The news is a low‑impact corporate action; traders are unlikely to adjust positions based on this filing alone.

03

What to watch

Potential future actions by the newly elected directors could influence company direction.

Relevance 6/10Novelty 4/10Timing: post‑market Aug 21 2026

Background

Aptevo Therapeutics filed a Form 8‑K to disclose the outcomes of its 2026 annual meeting, covering director elections, accounting firm ratification, executive compensation advisory vote, and stock incentive plan approval.

Company-level read

Ticker impact

$APVONeutralHigh confidence
Context

SEC Form 8‑K reports the results of Aptevo Therapeutics' annual shareholder meeting, including director elections and advisory votes.

Expected impact

Minimal price movement expected; the vote outcomes are routine governance items.

Evidence & confidence

The information is factual and directly sourced from the 8‑K, but the disclosed items are routine and low‑impact.

Market effects

None; governance update does not affect the biotech sector broadly.

None; limited to Aptevo shareholders.

None

Counterpoint

If the board changes signal strategic shift, some investors may view the election as a catalyst.

Key entities

  • Aptevo Therapeutics Inc.

    Biopharmaceutical company reporting its annual shareholder meeting results.

  • Baker Tilly US, LLP

    Independent registered public accounting firm ratified for 2026.

Related articles

$APVOMedAI 8/10

Why is Aptevo Therapeutics stock slumping today?

Aptevo Therapeutics (APVO) stock fell 17.3% pre-market to $2.15 despite reporting 93% clinical benefit rate in a trial for a treatment-resistant leukemia. The decline is attributed to 'sell the news' reaction, potential dilution from new shares, and bearish technical trends. The broader market showed mild gains, but not enough to offset APVO's challenges.

$APVOMedAI 8/10

Aptevo Therapeutics: Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

Aptevo Therapeutics (APVO) reported a 93% clinical benefit rate in TP53-mutated AML patients using its mipletamig triplet, nearly doubling published outcomes for venetoclax and azacitidine. The Phase 1b/2 RAINIER trial is ongoing, with regulatory interaction planned for 1H27. APVO focuses on developing novel immunotherapies for cancer.

$APVOMedAI 8/10

Aptevo Therapeutics: Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

Aptevo Therapeutics (NASDAQ:APVO) reported 2Q26 financial results and a business update. The company said mipletamig’s RAINIER Phase 1b/2 trial showed 87% clinical benefit and 81% remission in 31 evaluable unfit frontline AML patients, with dose optimization nearing completion and Phase 2 interaction expected in 1Q27. Aptevo appointed a new CSO, received a $1.5M non-dilutive grant for APVO451, and entered a 50/50 Niowave radiopharmaceutical collaboration. Cash was $9.8M at June 30, 2026.

$APVOLow

Aptevo Therapeutics Inc. (APVO): Results of Operations and Financial Condition

Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2 Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology Pipeline Non

$APVOMedAI 8/10

Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds

Aptevo Therapeutics (NASDAQ:APVO) closed a warrant inducement transaction where holders exercised existing warrants for cash to buy up to 254,922 shares at $4.03. The company issued inducement warrants for up to 1,274,610 shares. Separately, it completed a PIPE raising about $4.5 million gross at $4.03 per share, plus warrants. Net proceeds will fund working capital.

$APVOMedAI 8/10

Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds

Aptevo Therapeutics (NASDAQ:APVO) said it will induce holders to exercise existing common warrants for cash at a $4.03 exercise price, issuing inducement warrants for up to 1,274,610 shares. Separately, it plans a PIPE selling up to 861,708 shares (or pre-funded warrants) plus common warrants for up to 4,308,540 shares, also at $4.03. Gross proceeds total about $4.5 million, for working capital.